



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board

Thursday, June 11, 2026, 1:00pm

DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – Rachel Cain, PharmD, Chair
2. **Minutes - Approval of Minutes from the March 12, 2026 meeting**
3. **Old Business**
4. **DUR Drugs – Grid**
 - a) **DUR Traditional Drugs -- Non-Physician Administered Drugs**
 - a) Enbumyst™ (bumetanide nasal spray)
 - b) Kygevi™ (doxycitine and doxribtimine)
 - c) Lasix® ONYU (furosemide injection)
 - d) Lifyorli™ (relacorilant)
 - e) Myqorzo™ (aficamten)
 - f) Pivya™ (pivmecillinam)
 - g) Yuviwel® (navepegritide)
 - b) **Physician Administered Drugs (PADs)**
 - a) Casgevy™ (exagamglogene autotemcel)
 - b) Lyfgenia® (lovetibeglogene autotemcel)
5. **Topics for Discussion**
 - a) Concurrent Use of Opioids and Benzodiazepines
 - b) Concurrent Use of Opioids and Antipsychotics
 - c) Overlaps in Opioids, Benzodiazepines and Antipsychotics
 - d) Naloxone and Buprenorphine Utilization for Members on Opioids
6. **DUR Quarterly Newsletter (March 2026)**



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

7. **Prime Therapeutics Quarterly Pipeline – Complete Pipeline available on WebPortal (April 2026)**
8. **Reports**
 - a) ProDUR
 - b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
 - c) Utilization Analysis
9. **Public Comment**
10. **Adjournment**

DRAFT